miReven holds worldwide exclusive rights to the UWA miR-7 patents, creating a solid IP portfolio protecting the commercialisation of miR-7 as an anti-cancer therapeutic.
Our patent estate includes 4 patent families to date, 3 of which are published and have entered National Phase examination in multiple jurisdictions including the US and Europe.
|1||Method of Modulation of Expression of Epidermal Growth Factor Receptor (EGF-R) involving miRNA||US 8673872-Granted
EP 2061482 - Granted
|Method of use miR-7 cancer (EGFR-related)||Peter Leedman
|2||Methods and compositions for increasing sensitivity to tyrosine kinase inhibitors||AU 2010324530 - Granted
CA 2781572 - Pending
US 9051551- Granted
EU 2521555 - Granted
|Methods and composition for miR-7 combination therapy||Peter Leedman
|3||Cancer therapy using miRNAs||US 9795626 - Granted
EU 13847499.4 – under examination
IN 4209/DELNP/2015 - pending
CH 201380065503.0 - pending
|Methods of use miR-7 cancer (IGFR-related, melanoma)||Peter Leedman